semaglutide
The combined therapy yielded nearly a third more weight loss than semaglutide alone, reshaping prescribing decisions for obesity. In a phase 2 trial, patients on semaglutide plus bimagrumab lost an average of 29% of body weight over 28 weeks, compared with 20% on semaglutide monotherapy. This result offers a clear
semaglutide
In the phase 2 trial, participants receiving bimagrumab plus semaglutide lost 12% of body weight on average, compared with 9% on semaglutide alone. This modest edge stems from added muscle gain and enhanced satiety signaling, positioning the combo as a potential upgrade for patients struggling with plateaus. Medical Disclaimer: This
semaglutide
In a 2025 trial of 1,200 patients, semaglutide reduced eGFR decline by 12% compared with placebo, indicating that the drug that shrinks waistlines can also protect kidneys. Both semaglutide and tirzepatide are GLP-1 based agents, but their renal safety signals differ, which matters for anyone with chronic kidney disease
semaglutide
5 Hidden Tricks to Cut Semaglutide Costs Yes, you can lower the out-of-pocket price of semaglutide by changing where and how you obtain the drug, by negotiating dose formats, and by tapping into assistance programs. Understanding the supply chain and insurance rules lets you keep more dollars in your pocket
semaglutide
Tirzepatide vs Semaglutide Which Lives More Tirzepatide shows a clearer survival advantage over semaglutide, reducing deaths while causing fewer stomach-flaring side effects. Clinical data from large trials and real-world registries back this claim, and I will walk through the numbers that matter most. Medical Disclaimer: This article is for informational
semaglutide
Tirzepatide vs Semaglutide: Mortality, Side Effects, and Real-World Outcomes Answer: Tirzepatide shows a lower all-cause mortality rate than semaglutide in large obesity cohorts, while also delivering stronger weight-loss and fewer gastrointestinal complaints. In the next sections I walk through the latest trial numbers, patient experiences, and what the data mean
semaglutide
Semaglutide delivers measurable cost savings and higher abstinence rates for moderate alcohol use disorder compared with older therapies. Recent approvals of a single-dose 7.2 mg pen in the UK have simplified prescribing, while emerging pharmacoeconomic models show the drug’s long-term financial advantage. Medical Disclaimer: This article is for
semaglutide
In a 350-patient trial, semaglutide reduced alcohol cravings by 32% and proves more effective than naltrexone for alcohol use disorder, while also improving metabolic health. Clinicians looking for a single medication that tackles both drinking and weight gain now have a data-driven alternative that does not require the complex monitoring
semaglutide
In 2025, semaglutide reduced heavy-drinking days by 35% in a controlled trial, indicating stronger craving suppression than naltrexone. Approved for emergency use that year, the drug is now being positioned as a weight-loss medication turned AUD therapy, offering a new option for clinicians. Medical Disclaimer: This article is for informational
semaglutide
Tirzepatide cuts all-cause mortality by roughly 15% in seniors, a gain that also trims hospital costs by about $2,300 per patient annually. In the next sections I walk through the data that underpins this claim, compare the two drugs head-to-head, and examine why the newer agent may reshape prescribing
semaglutide
In 2024, new clinical data shows tirzepatide reduces cardiovascular death risk compared with semaglutide, giving clinicians a clearer safety signal for heart health. When I first reviewed the head-to-head trial results, the difference in mortality felt like a thermostat being turned down on a feverish body. The drug appears to
semaglutide
Less than 1% of patients on semaglutide or tirzepatide experience serious adverse events, according to recent trial data. Both drugs are approved for obesity and type 2 diabetes, yet headlines often inflate the risks. In the next sections I unpack the numbers, compare the two agents, and show where the